Reply to A. Shinde et al

Affiliations

¹ Harriet M. Kluger, MD, Yale School of Medicine, New Haven, CT; Kim A. Margolin, MD, City of Hope, Duarte, CA; Michael A. Davies, MD, PhD, MD Anderson Cancer Center, Houston, TX; Georgina V. Long, PhD, The University of Sydney, Sydney, NSW, Australia; Hussein A. Tawbi, MD, PhD, MD Anderson Cancer Center, Houston, TX; and Sarah B. Goldberg, MD and Veronica L. Chiang, MD, Yale School of Medicine, New Haven, CT.

Comment

Harriet M Kluger et al. J Clin Oncol. 2019.

. 2019 Apr 20;37(12):1031-1032.

doi: 10.1200/JCO.18.02463. Epub 2019 Feb 26.

¹ Harriet M. Kluger, MD, Yale School of Medicine, New Haven, CT; Kim A. Margolin, MD, City of Hope, Duarte, CA; Michael A. Davies, MD, PhD, MD Anderson Cancer Center, Houston, TX; Georgina V. Long, PhD, The University of Sydney, Sydney, NSW, Australia; Hussein A. Tawbi, MD, PhD, MD Anderson Cancer Center, Houston, TX; and Sarah B. Goldberg, MD and Veronica L. Chiang, MD, Yale School of Medicine, New Haven, CT.

No abstract available

Comment on

Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II Trial.
Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, Goldberg SB, Jilaveanu LB. Kluger HM, et al. J Clin Oncol. 2019 Jan 1;37(1):52-60. doi: 10.1200/JCO.18.00204. Epub 2018 Nov 8. J Clin Oncol. 2019. PMID: 30407895 Free PMC article. Clinical Trial.
Can Immunotherapy Replace Radiotherapy in Melanoma Brain Metastases?
Shinde A, Li R, Amini A, Glaser S. Shinde A, et al. J Clin Oncol. 2019 Apr 20;37(12):1030-1031. doi: 10.1200/JCO.18.01982. Epub 2019 Feb 26. J Clin Oncol. 2019. PMID: 30807232 No abstract available.